Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA.
Exp Hematol. 2013 Oct;41(10):870-881.e2. doi: 10.1016/j.exphem.2013.05.005. Epub 2013 Jun 4.
Stem cell factor-dependent KIT activation is an essential process for mast cell homeostasis. The two major splice variants of KIT differ by the presence or absence of four amino acids (GNNK) at the juxta-membrane region of the extracellular domain. We hypothesized that the expression pattern of these variants differs in systemic mastocytosis and that transcripts containing the KIT D816V mutation segregate preferentially to one GNNK variant. A quantitative real-time PCR assay to assess GNNK(-) and GNNK(+) transcripts from bone marrow mononuclear cells was developed. The GNNK(-)/GNNK(+) copy number ratio showed a trend toward a positive correlation with the percentage of neoplastic mast cell involvement, and KIT D816V containing transcripts displayed a significantly elevated GNNK(-)/GNNK(+) copy number ratio. Relative expression of only the GNNK(-) variant correlated with increasing percentage of neoplastic mast cell involvement. A mast cell transfection system revealed that the GNNK(-) isoform of wild type KIT was associated with increased granule formation, histamine content, and growth. When accompanying the KIT D816V mutation, the GNNK(-) isoform enhanced cytokine-free metabolism and moderately reduced sensitivity to the tyrosine kinase inhibitor, PKC412. These data suggest that neoplastic mast cells favor a GNNK(-) variant predominance, which in turn enhances the activating potential of the KIT D816V mutation and thus could influence therapeutic sensitivity in systemic mastocytosis.
干细胞因子依赖性 KIT 激活是肥大细胞动态平衡的必要过程。KIT 的两个主要剪接变体在细胞外结构域的近膜区存在或不存在四个氨基酸(GNNK)。我们假设这些变体在系统性肥大细胞中的表达模式不同,并且包含 KIT D816V 突变的转录本优先分配到一个 GNNK 变体。开发了一种定量实时 PCR 测定法,以评估骨髓单核细胞中的 GNNK(-)和 GNNK(+)转录本。GNNK(-)/GNNK(+)拷贝数比与肿瘤性肥大细胞参与的百分比呈正相关趋势,并且包含 KIT D816V 的转录本显示出明显升高的 GNNK(-)/GNNK(+)拷贝数比。仅 GNNK(-)变体的相对表达与肿瘤性肥大细胞参与的百分比增加相关。肥大细胞转染系统显示野生型 KIT 的 GNNK(-) 异构体与颗粒形成、组胺含量和生长增加相关。当伴随 KIT D816V 突变时,GNNK(-)异构体增强了无细胞因子代谢,并且适度降低了对酪氨酸激酶抑制剂 PKC412 的敏感性。这些数据表明,肿瘤性肥大细胞倾向于 GNNK(-)变体优势,这反过来又增强了 KIT D816V 突变的激活潜力,从而可能影响系统性肥大细胞中的治疗敏感性。